Total Payments
$23,114
2024 Payments
$761.01
Companies
45
Transactions
799
Medicare Patients
2,774
Medicare Billing
$1.9M
Payment Breakdown by Category
Food & Beverage$15,213 (65.8%)
Other$7,844 (33.9%)
Education$56.87 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,213 | 778 | 65.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,844 | 18 | 33.9% |
| Education | $56.87 | 2 | 0.2% |
| Unspecified | $0 | 1 | 0.0% |
Payments by Type
General
$23,114
798 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Aurinia Pharma U.S., Inc. | $6,924 | 10 | $0 (2023) |
| Amgen Inc. | $2,167 | 106 | $0 (2024) |
| Janssen Biotech, Inc. | $1,510 | 89 | $0 (2023) |
| GENZYME CORPORATION | $1,395 | 32 | $0 (2022) |
| ABBVIE INC. | $1,269 | 70 | $0 (2024) |
| PFIZER INC. | $1,233 | 75 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $1,181 | 50 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $947.31 | 68 | $0 (2023) |
| GlaxoSmithKline, LLC. | $784.22 | 31 | $0 (2024) |
| Lilly USA, LLC | $732.34 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $761.01 | 8 | Amgen Inc. ($279.47) |
| 2023 | $1,309 | 43 | Janssen Biotech, Inc. ($413.91) |
| 2022 | $2,012 | 82 | Janssen Scientific Affairs, LLC ($339.16) |
| 2021 | $9,220 | 100 | Aurinia Pharma U.S., Inc. ($6,883) |
| 2020 | $1,475 | 95 | AbbVie Inc. ($249.42) |
| 2019 | $3,205 | 195 | Amgen Inc. ($371.48) |
| 2018 | $2,097 | 151 | Amgen Inc. ($341.36) |
| 2017 | $3,036 | 125 | SANOFI-AVENTIS U.S. LLC ($500.00) |
All Payment Transactions
799 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | Cash or cash equivalent | $113.96 | General |
| Category: Immunology | ||||||
| 08/26/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $129.65 | General |
| Category: Immunology | ||||||
| 08/07/2024 | E.R. Squibb & Sons, L.L.C. | ORENCIA (Biological) | Food and Beverage | Cash or cash equivalent | $15.94 | General |
| Category: Immunology | ||||||
| 07/09/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $96.99 | General |
| Category: IMMUNOLOGY | ||||||
| 04/25/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: IMMUNOLOGY | ||||||
| 03/28/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $145.62 | General |
| Category: Inflammation | ||||||
| 03/13/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $118.30 | General |
| Category: Inflammation/Rare Disease | ||||||
| 01/18/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/08/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.73 | General |
| Category: KRYSTEXXA | ||||||
| 11/16/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $101.97 | General |
| Category: KRYSTEXXA | ||||||
| 11/10/2023 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological) | Food and Beverage | In-kind items and services | $115.97 | General |
| Category: Immunology | ||||||
| 09/12/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: KRYSTEXXA | ||||||
| 08/29/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: KRYSTEXXA | ||||||
| 08/14/2023 | Horizon Therapeutics plc | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: KRYSTEXXA | ||||||
| 04/26/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/25/2023 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological) | Food and Beverage | In-kind items and services | $115.63 | General |
| Category: Immunology | ||||||
| 04/25/2023 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: Immunology | ||||||
| 04/24/2023 | Janssen Biotech, Inc. | SIMPONI ARIA (Biological) | Food and Beverage | In-kind items and services | $16.86 | General |
| Category: Immunology | ||||||
| 04/21/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $21.59 | General |
| Category: Dermatology | ||||||
| 04/18/2023 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $100.00 | General |
| 04/17/2023 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: IMMUNOLOGY | ||||||
| 04/13/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/13/2023 | Fresenius Kabi USA, LLC | — | Food and Beverage | In-kind items and services | $15.79 | General |
| 04/10/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.54 | General |
| 04/06/2023 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 628 | 3,292 | $544,370 | $145,872 |
| 2022 | 17 | 777 | 12,892 | $1.4M | $504,836 |
| 2021 | 13 | 653 | 13,622 | $1.4M | $632,309 |
| 2020 | 12 | 716 | 11,784 | $1.3M | $594,134 |
Total Patients
2,774
Total Services
41,590
Medicare Billing
$1.9M
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 225 | 559 | $209,990 | $56,409 | 26.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 31 | 173 | $81,200 | $19,018 | 23.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 11 | 901 | $51,345 | $16,565 | 32.3% |
| J7322 | Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg | Office | 2023 | 13 | 1,008 | $45,360 | $13,203 | 29.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 122 | 186 | $48,210 | $12,430 | 25.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 55 | 55 | $30,315 | $7,275 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 44 | $22,320 | $6,307 | 28.3% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 21 | 47 | $20,303 | $5,472 | 27.0% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 36 | 58 | $14,223 | $3,600 | 25.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 13 | 42 | $9,630 | $2,513 | 26.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 14 | 90 | $8,690 | $2,337 | 26.9% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 44 | 116 | $1,890 | $577.57 | 30.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 13 | $895.00 | $165.49 | 18.5% |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 2022 | 15 | 8,850 | $635,625 | $295,118 | 46.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 253 | 650 | $234,000 | $65,243 | 27.9% |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | Office | 2022 | 12 | 1,567 | $269,460 | $60,304 | 22.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 33 | 180 | $84,600 | $21,718 | 25.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 14 | 902 | $40,500 | $15,537 | 38.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 122 | 194 | $47,530 | $14,294 | 30.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 70 | 70 | $38,500 | $9,165 | 23.8% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2022 | 24 | 61 | $26,145 | $7,491 | 28.7% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 56 | 92 | $22,345 | $5,727 | 25.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 32 | 38 | $18,240 | $5,289 | 29.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 15 | 62 | $5,890 | $1,639 | 27.8% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 12 | 14 | $3,640 | $950.96 | 26.1% |
About Dr. Michael Guma, D.O
Dr. Michael Guma, D.O is a Rheumatology healthcare provider based in North Arlington, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376655407.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Guma, D.O has received a total of $23,114 in payments from pharmaceutical and medical device companies, with $761.01 received in 2024. These payments were reported across 799 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($15,213).
As a Medicare-enrolled provider, Guma has provided services to 2,774 Medicare beneficiaries, totaling 41,590 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location North Arlington, NJ
- Active Since 08/31/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1376655407
Products in Payments
- LUPKYNIS (Drug) $6,924
- ORENCIA (Biological) $1,105
- Enbrel (Biological) $1,085
- KEVZARA (Biological) $1,048
- SIMPONI ARIA (Biological) $1,037
- XELJANZ (Drug) $1,035
- BENLYSTA (Biological) $784.22
- KRYSTEXXA (Biological) $665.61
- COSENTYX (Biological) $618.42
- RINVOQ (Biological) $525.59
- SYNVISC-ONE (Device) $500.00
- TREMFYA (Drug) $454.99
- KEVZARA (Drug) $413.36
- Humira (Biological) $370.76
- TALTZ (Drug) $365.54
- EUFLEXXA (Device) $309.14
- Cimzia (Drug) $303.56
- OFEV (Drug) $284.91
- Actemra (Biological) $281.62
- Prolia (Biological) $251.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.